| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Review |
1 From the Department of Radiology (E.J.C.A., R.W., R.S.) and the Myeloma Institute (A.B.T.F., B.B.), University of Arkansas for Medical Sciences, 4301 W Markham, Slot 596, Little Rock, AR 72205. Received April 22, 2002; revision requested June 19; revision received March 4, 2003; accepted March 17. Address correspondence to E.J.C.A. (e-mail: angtuacoedgardoj@uams.edu).
Multiple myeloma (MM) is a malignant clonal neoplasm of plasma cells of B-lymphocyte origin that commonly results in overproduction of large amounts of monoclonal immunoglobulins. Important advances in the therapeutic management of this disease in the past decade have resulted in higher rates of durable complete remission, prolonged event-free survival, and improved overall survival. Clearer understanding of the effects of abnormal plasma cells on bone has led to therapeutic approaches that help prevent vertebral body fractures. Current imaging technologies and, in particular, survey marrow studies with magnetic resonance (MR) imaging have improved detection of the extent and location of disease in MM patients. In newly diagnosed cases, MR surveys of the axial skeleton accurately demonstrate the extent of disease—diffuse or focal involvement—and the presence of associated compression fractures and cord compression. After treatment, MR images show the effects of treatment and the presence of residual disease. Multiple sites of focal bone lesions detected on MR studies allow a more appropriate choice of biopsy site than the usual random iliac marrow biopsy. Use of MR to determine biopsy sites and computed tomographic guidance for biopsy performance have increased the safety and accuracy of sampling. These biopsies have resulted in increased identification of cytogenetic abnormalities, particularly the presence of chromosome 13 deletion, which is a grave prognostic indicator in MM.
© RSNA, 2004
Index terms: Bone marrow, diseases, 48.3452 • Bones, CT, 48.12111 • Bones, MR, 48.121411, 48.121412, 48.121413, 48.121415 • Myeloma, 48.3452 • Review
This article has been cited by other articles:
|
|
 |
|
  M HORGER, P PEREIRA, C D CLAUSSEN, L KANZ, R VONTHEIN, B DENECKE, and C DRIESSEN Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters Br. J. Radiol., May 1, 2008; 81(965): 386 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fonti, B. Salvatore, M. Quarantelli, C. Sirignano, S. Segreto, F. Petruzziello, L. Catalano, R. Liuzzi, B. Rotoli, S. Del Vecchio, et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma J. Nucl. Med., February 1, 2008; 49(2): 195 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. O. Oyajobi, S. Munoz, R. Kakonen, P. J. Williams, A. Gupta, C. L. Wideman, B. Story, B. Grubbs, A. Armstrong, W. C. Dougall, et al. Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging Mol. Cancer Ther., June 1, 2007; 6(6): 1701 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.P. Ojha, D. Prabhakar, E. Evans, K. Lowery, R. Thertulien, and L.A. Fischbach RE: Abou-Jawde et al. The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma Haematologica, April 1, 2007; 92(4): e46 - e46. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Walker, B. Barlogie, J. Haessler, G. Tricot, E. Anaissie, J. D. Shaughnessy Jr, J. Epstein, R. van Hemert, E. Erdem, A. Hoering, et al. Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications J. Clin. Oncol., March 20, 2007; 25(9): 1121 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Zamagni, C. Nanni, F. Patriarca, E. Englaro, P. Castellucci, O. Geatti, P. Tosi, P. Tacchetti, D. Cangini, G. Perrone, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma Haematologica, January 1, 2007; 92(1): 50 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dankerl, P. Liebisch, G. Glatting, C. Friesen, N. M. Blumstein, D. Kocot, C. Wendl, D. Bunjes, and S. N. Reske Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience Radiology, December 19, 2006; (2006) 2422051980. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. S. Stacy, R. S. Mahal, and T. D. Peabody Staging of bone tumors: a review with illustrative examples. Am. J. Roentgenol., April 1, 2006; 186(4): 967 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Boshell, R. Sabharwal, R. Keen, P. Coleman, P. Vladica, and S. D. Roger Fistula dysfunction secondary to a subcutaneous myelomatous deposit Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2827 - 2829. [Full Text] [PDF]
|
|
|
|
|
|
E. Even-Sapir Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities J. Nucl. Med., August 1, 2005; 46(8): 1356 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Bredella, L. Steinbach, G. Caputo, G. Segall, and R. Hawkins Value of FDG PET in the Assessment of Patients with Multiple Myeloma Am. J. Roentgenol., April 1, 2005; 184(4): 1199 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Pace, S. Del Vecchio, M. Salvatore, R. C. Walker, E. Angtuaco, R. Sethi, A. Fassas, and B. Barlogie Technetium 99m Sestamibi in Multiple Myeloma * Dr Walker and colleagues respond: Radiology, January 1, 2005; 234(1): 312 - 313. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Mulligan, E. J. C. Angtuaco, A. B. T. Fassas, R. Walker, R. Sethi, and B. Barlogie Skeletal Abnormalities in Multiple Myeloma * Dr Angtuaco and colleagues respond: Radiology, January 1, 2005; 234(1): 313 - 314. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |
